PRIMECAP Management acquired 8.38M Allogene Therapeutics shares worth $15.8M. That's 0.01% of their equity portfolio (242nd largest holding). The investor owns 2.98% of the outstanding Allogene Therapeutics stock. The first Allogene Therapeutics trade was made in Q4 2020. Since then PRIMECAP Management bought shares fifteen more times and sold shares on six occasions. The investor's estimated purchase price is $123M, resulting in a loss of 87%.